uniQure N.V. (QURE)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | BIOTECHNOLOGY & LIFE SCIENCES |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | Matthew C. Kapusta |
| Employees: | 500 |
| Web site: | uniqure.com |
|
PAASHEUVELWEG 25A, AMSTERDAM, P7, 1105 BP
1-339-970-7000
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.
Please log in first to see chart